Sarepta Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $563.7M | $928.0M | $2.12B |
| FY2022 | $1.54B | $385.0M | $966.8M |
| FY2023 | $1.24B | $859.3M | $428.4M |
| FY2024 | $1.14B | $1.53B | $1.10B |
| FY2025 | $140.5M | $1.14B | $801.3M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $563.7M | $928.0M | $2.12B |
| FY2022 | $1.54B | $385.0M | $966.8M |
| FY2023 | $1.24B | $859.3M | $428.4M |
| FY2024 | $1.14B | $1.53B | $1.10B |
| FY2025 | $140.5M | $1.14B | $801.3M |